- Home
- TPIC vs RPTX Comparison
TPIC vs RPTX Comparison
Compare TPIC & RPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TPIC
- RPTX
- Stock Information
- Founded
- TPIC 1968
- RPTX 2016
- Country
- TPIC United States
- RPTX Canada
- Employees
- TPIC N/A
- RPTX N/A
- Industry
- TPIC Industrial Machinery/Components
- RPTX Biotechnology: Pharmaceutical Preparations
- Sector
- TPIC Industrials
- RPTX Health Care
- Exchange
- TPIC Nasdaq
- RPTX Nasdaq
- Market Cap
- TPIC 35.5M
- RPTX 38.3M
- IPO Year
- TPIC 2016
- RPTX 2020
- Fundamental
- Price
- TPIC $0.87
- RPTX $1.36
- Analyst Decision
- TPIC Hold
- RPTX Strong Buy
- Analyst Count
- TPIC 6
- RPTX 3
- Target Price
- TPIC $1.86
- RPTX $4.50
- AVG Volume (30 Days)
- TPIC 337.8K
- RPTX 502.5K
- Earning Date
- TPIC 05-12-2025
- RPTX 05-20-2025
- Dividend Yield
- TPIC N/A
- RPTX N/A
- EPS Growth
- TPIC N/A
- RPTX N/A
- EPS
- TPIC N/A
- RPTX N/A
- Revenue
- TPIC $1,331,131,000.00
- RPTX $53,477,000.00
- Revenue This Year
- TPIC $8.85
- RPTX N/A
- Revenue Next Year
- TPIC $7.52
- RPTX $7.14
- P/E Ratio
- TPIC N/A
- RPTX N/A
- Revenue Growth
- TPIC N/A
- RPTX 4.58
- 52 Week Low
- TPIC $0.64
- RPTX $0.89
- 52 Week High
- TPIC $5.75
- RPTX $4.29
- Technical
- Relative Strength Index (RSI)
- TPIC 47.43
- RPTX 59.23
- Support Level
- TPIC $0.93
- RPTX $1.31
- Resistance Level
- TPIC $1.04
- RPTX $1.48
- Average True Range (ATR)
- TPIC 0.09
- RPTX 0.10
- MACD
- TPIC 0.02
- RPTX 0.00
- Stochastic Oscillator
- TPIC 46.71
- RPTX 57.14
About TPIC TPI Composites Inc.
TPI Composites Inc is engaged in manufacturing composite wind blades. The company operates in wind energy and transportation industries where it manufactures structures for a bus, rail, theme parks, and trucks. Geographically the segments are divided into the U.S, Asia, Mexico, EMEA and India where the Mexico segment derives a majority of revenue.
About RPTX Repare Therapeutics Inc.
Repare Therapeutics Inc is a precision medicine oncology company focused on the development of synthetic lethality-based therapies for patients with cancer. The Company's focus is the research, development and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations.